A2A Adenosine Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
A2A Adenosine Receptor Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
A2A ADENOSINE RECEPTOR is a gene/protein encoding a key neuronal protein involved in synaptic function, signal transduction, and cellular homeostasis. Dysfunction of A2A ADENOSINE RECEPTOR is associated with neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease), Parkinson's disease, and related disorders.
Structure
The adenosine A2a receptor (A2AR) is a seven-transmembrane GPCR with an extracellular N-terminus and intracellular C-terminus. The receptor contains:
Seven transmembrane helices (TM1-TM7)
Three extracellular loops (ECL1-ECL3)
Three intracellular loops (ICL1-ICL3)
Orthosteric adenosine binding site within the transmembrane bundle
Crystal structures have revealed the inactive and active conformations, providing insights into GPCR signaling and drug binding.
Normal Function
A2AR couples to Gs/olf proteins, stimulating adenylate cyclase activity and increasing intracellular cAMP levels. In the brain:
Striatal function: A2AR is highly expressed in the striatum where it modulates dopamine D2 receptor (D2R) signaling through heteromeric receptor complexes
Motor control: A2AR activation promotes locomotion; antagonism reduces motor inhibition
Neuroinflammation: A2AR on [microglia](/cell-types/microglia-neuroinflammation) and [astrocytes](/entities/astrocytes) modulates inflammatory responses
Sleep regulation: A2AR in the basal forebrain promotes wakefulness
The study of A2A Adenosine Receptor Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
External Links
[PubMed](https://pubmed.ncbi.nlm.nih.gov/) - Biomedical literature
[Alzheimer's Disease Neuroimaging Initiative](https://adni.loni.usc.edu/) - Research data
[Allen Brain Atlas](https://brain-map.org/) - Brain gene expression data
References
[Chen JF, et al, Adenosine A2A receptors: A major target for neuroprotection (2020)](https://pubmed.ncbi.nlm.nih.gov/32333542/)
[Kase D, et al, A2A adenosine receptor and Parkinson's disease: New strategies (2019)](https://pubmed.ncbi.nlm.nih.gov/31284019/)
[Wei CJ, et al, A2A receptors in basal ganglia and stroke (2019)](https://pubmed.ncbi.nlm.nih.gov/30683274/)
[Jenner P, et al, A2A antagonists as novel anti-parkinsonian agents (2020)](https://pubmed.ncbi.nlm.nih.gov/32851782/)
[Yu L, et al, Adenosine A2A receptors in neuroinflammation (2021)](https://pubmed.ncbi.nlm.nih.gov/33775628/)
[Schwarzschild MA, et al, Targeting A2A receptors for neuroprotection in PD (2019)](https://pubmed.ncbi.nlm.nih.gov/31003866/)
[Morelli M, et al, A2A adenosine receptor antagonism and levodopa-induced dyskinesia (2018)](https://pubmed.ncbi.nlm.nih.gov/29465074/)
[Cieśla M, et al, A2A receptor blockade in models of neurodegeneration (2019)](https://pubmed.ncbi.nlm.nih.gov/31164370/)